Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Zylorion Health Inc. is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions currently under review. These matters are being handled by 2 distinct examiners, ensuring that the company's applications are evaluated independently. This distribution across different personnel helps mitigate the risk associated with any single examiner's interpretation of patent law.
The company's prosecution efforts are situated within 2 distinct art units. This indicates that the 2 pending office actions involve different technical classifications within the broader life sciences field. OTTON, ALICIA L is the busiest examiner for the portfolio, currently responsible for 1 pending office action.
With 2 pending office actions and 2 distinct examiners, the company has a balanced workload at the USPTO. OTTON, ALICIA L manages 1 pending office action, which is half of the total active matters. The presence of 2 distinct art units suggests that the company is pursuing multiple technical paths or applications within its Biotechnology & Pharmaceuticals research.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18877636 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | OTTON, ALICIA L | — |
| 18942043 | CO-ADMINISTRATION OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN WITH AN ATYPICAL ANTIPSYCHOTIC | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18942043 | CO-ADMINISTRATION OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN WITH AN ATYPICAL ANTIPSYCHOTIC | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18877636 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | OTTON, ALICIA L | 1629 | §102§103Other | Non-Final OA | — | Pending | Dec 20, 2024 |
| 18942043 | CO-ADMINISTRATION OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN WITH AN ATYPICAL ANTIPSYCHOTIC | WELLS, LAUREN QUINLAN | 1622 | §103§112Other | Non-Final OA | — | Pending | Nov 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZylorion Health Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Alicia L Otton has the most, with 1 of Zylorion Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
